Abstract
Urine toxicology screen is a potentially useful tool in monitoring the patient’s adherence to treatment. It is underutilized is many settings but may also be overutilized in others. This chapter summarizes the reasons and recommended frequency for this test. It also discusses the various types of urine toxicology screen, the expected results based on medication’s metabolism, as well as potential drawbacks such as false positives and negatives.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AED:
-
Antiepileptic drug
- CLIA:
-
Clinical Laboratory Improvement Amendments
- EPPD:
-
2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyr-rolidine
- ER:
-
Emergency Room
- EtOH:
-
Ethanol
- GM:
-
Gas chromatography
- HPLC:
-
High performance liquid chromatography
- IA:
-
Immunoassay
- LC/MS/MS:
-
Liquid chromatography tandem mass spectro-metry
- LSD:
-
Lysergic Acid Diethylamide
- MDMA:
-
3,4-Methylenedioxy-N-methylamphetamine
- MDPV:
-
Methylenedioxypyrovalerone
- MMTP:
-
Methadone Maintenance Treatment Program
- MS:
-
Mass spectrometry
- PCP:
-
Phencyclidine
- POC:
-
Point of care
- RDS:
-
Random drug screen
- TCA:
-
Tricyclic
- THC:
-
Tetrahydrocannabinol
- UDS:
-
Urine drug screen
- UTOX:
-
Urine toxicology
References
Tenore PL. Advanced urine toxicology testing. J Addict Dis. 2010;29(4):436–48.
Official Disability Guidelines (ODG), Treatment Index, 11th Edition (web), 2013, Pain (Chronic).
Chelminski PR, Ives TJ, Felix KM, Prakken SD, Miller TM, Perhac JS, Malone RM, Bryant ME, DeWalt DA, Pignone MP. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res. 2005;5(1):3.
Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, Jordan AE, Colson J. Urine drug testing in chronic pain. Pain Physician. 2011;14(2):123–43.
Mikel C, Pesce AJ, Rosenthal M, West C. Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety. Clin Chim Acta. 2012;413(15–16):1199–202.
Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66–76.
Starrels JL, Becker WC, Alford DP, Kapoor A, Wlliams AR, Turner BJ. Systemaitc review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712–20.
Markway EC, Baker SN. A review of the methods, interpretation, and limitations of the urine drug screen. Orthopedics. 2011;34(11):877–81.
Nafziger AN, Bertino Jr JS. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009;25(1):73–9.
Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–24.
Redwood Toxicolog Laboratory. Laboratory testing reference guide. http://www.redwoodtoxicology.com/documents/3034_refguide.pdf. Accessed 10 Feb 2013.
Ameritox Medication Monitoring Solutions. Drug test quick reference guide. Baltimore: Ameritox Ltd; 2010.
DuPont RL, Baumgartner WA. Drug testing by urine and hair analysis: complementary features and scientific issues. Forensic Sci Int. 1995;70(1–3):63–76.
Pesce A, West C, Egan City K, Strickland J. Interpretation of urine drug testing in pain patients. Pain Med. 2012;13(7):868–85. doi:10.1111/j.1526-4637.2012.01350.x. Epub 2012 Apr 11.
Fraser AD, Bryan W, Isner AF. Urinary screening for midazolam and its major metabolites with the Abbott ADx and TDx analyzers and the EMIT d.a.u. benzodiazepine assay with confirmation by GC/MS. J Anal Toxicol. 1991;15(1):8–12.
Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26(2):200–5.
McKinney AR, Suann CJ, Stenhouse AM. The detection of modafinil and its major metabolite in equine urine by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(10):1217–20.
Wong EC, Koenig J, Turk J. Potential interference of cyclobenzaprine with HPLC measurement of Amitriptyline and Nortriptyline: resolution by GC-MS analysis. J Anal Toxicol. 1995;19(4):2118–24.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ho, J. (2015). Urine Toxicology Screen. In: Sackheim, K. (eds) Pain Management and Palliative Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2462-2_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2462-2_6
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2461-5
Online ISBN: 978-1-4939-2462-2
eBook Packages: MedicineMedicine (R0)